Effects of commercially available soy products on PSA in androgen-deprivation-naïve and castration-resistant prostate cancer

Monika Joshi, Nicole M. Agostino, Rebecca Gingrich, Joseph J. Drabick

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

OBJECTIVE:: No standard therapeutic option exists for men with prostate cancer who have failed local therapy, have no gross metastatic disease, and whose only manifestation of disease is a rising prostate-specific antigen (PSA) level. Soy products are able to affect PSA kinetics in some men with prostate cancer, and this effect has been attributed to the decreased expression of the androgen receptor and other mechanisms. METHODS:: We treated 10 men with rising PSA levels after radical prostatectomy and salvage radiotherapy with commercially available soy products. Scans revealed no gross metastatic disease. Three men also had been receiving androgen-deprivation therapy (ADT) and had rising PSA levels that were consistent with castration-resistant (CR) disease. We reported the results of this modality on PSA levels, PSA kinetics, and the duration of PSA response. RESULTS:: Responses occurred in 4 of 7 (57%) patients with ADT-naïve disease and 1 of 3 (33%) patients with CR disease. The median duration of treatment response was 24 months. The overall clinical benefit, therefore, was noted in 5 of 10 (50%) patients. Therapy was well tolerated. CONCLUSIONS:: Our findings are fairly congruent with what has been described in the literature on the use of this modality in prostate cancer. We used commercially available soy products. We also show that soy can provide benefit in CR prostate cancer. Our clinical experience suggests that soy supplementation using commercially available soy products can have durable beneficial effects on PSA levels and PSA kinetics in some men with prostate cancer.

Original languageEnglish (US)
Pages (from-to)736-740
Number of pages5
JournalSouthern Medical Journal
Volume104
Issue number11
DOIs
StatePublished - Nov 1 2011

Fingerprint

Castration
Prostate-Specific Antigen
Androgens
Prostatic Neoplasms
Therapeutics
Androgen Receptors
Prostatectomy
Radiotherapy

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{d98038ec047a47ba851311795574e35d,
title = "Effects of commercially available soy products on PSA in androgen-deprivation-na{\"i}ve and castration-resistant prostate cancer",
abstract = "OBJECTIVE:: No standard therapeutic option exists for men with prostate cancer who have failed local therapy, have no gross metastatic disease, and whose only manifestation of disease is a rising prostate-specific antigen (PSA) level. Soy products are able to affect PSA kinetics in some men with prostate cancer, and this effect has been attributed to the decreased expression of the androgen receptor and other mechanisms. METHODS:: We treated 10 men with rising PSA levels after radical prostatectomy and salvage radiotherapy with commercially available soy products. Scans revealed no gross metastatic disease. Three men also had been receiving androgen-deprivation therapy (ADT) and had rising PSA levels that were consistent with castration-resistant (CR) disease. We reported the results of this modality on PSA levels, PSA kinetics, and the duration of PSA response. RESULTS:: Responses occurred in 4 of 7 (57{\%}) patients with ADT-na{\"i}ve disease and 1 of 3 (33{\%}) patients with CR disease. The median duration of treatment response was 24 months. The overall clinical benefit, therefore, was noted in 5 of 10 (50{\%}) patients. Therapy was well tolerated. CONCLUSIONS:: Our findings are fairly congruent with what has been described in the literature on the use of this modality in prostate cancer. We used commercially available soy products. We also show that soy can provide benefit in CR prostate cancer. Our clinical experience suggests that soy supplementation using commercially available soy products can have durable beneficial effects on PSA levels and PSA kinetics in some men with prostate cancer.",
author = "Monika Joshi and Agostino, {Nicole M.} and Rebecca Gingrich and Drabick, {Joseph J.}",
year = "2011",
month = "11",
day = "1",
doi = "10.1097/SMJ.0b013e3182335151",
language = "English (US)",
volume = "104",
pages = "736--740",
journal = "Southern Medical Journal",
issn = "0038-4348",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

Effects of commercially available soy products on PSA in androgen-deprivation-naïve and castration-resistant prostate cancer. / Joshi, Monika; Agostino, Nicole M.; Gingrich, Rebecca; Drabick, Joseph J.

In: Southern Medical Journal, Vol. 104, No. 11, 01.11.2011, p. 736-740.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of commercially available soy products on PSA in androgen-deprivation-naïve and castration-resistant prostate cancer

AU - Joshi, Monika

AU - Agostino, Nicole M.

AU - Gingrich, Rebecca

AU - Drabick, Joseph J.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - OBJECTIVE:: No standard therapeutic option exists for men with prostate cancer who have failed local therapy, have no gross metastatic disease, and whose only manifestation of disease is a rising prostate-specific antigen (PSA) level. Soy products are able to affect PSA kinetics in some men with prostate cancer, and this effect has been attributed to the decreased expression of the androgen receptor and other mechanisms. METHODS:: We treated 10 men with rising PSA levels after radical prostatectomy and salvage radiotherapy with commercially available soy products. Scans revealed no gross metastatic disease. Three men also had been receiving androgen-deprivation therapy (ADT) and had rising PSA levels that were consistent with castration-resistant (CR) disease. We reported the results of this modality on PSA levels, PSA kinetics, and the duration of PSA response. RESULTS:: Responses occurred in 4 of 7 (57%) patients with ADT-naïve disease and 1 of 3 (33%) patients with CR disease. The median duration of treatment response was 24 months. The overall clinical benefit, therefore, was noted in 5 of 10 (50%) patients. Therapy was well tolerated. CONCLUSIONS:: Our findings are fairly congruent with what has been described in the literature on the use of this modality in prostate cancer. We used commercially available soy products. We also show that soy can provide benefit in CR prostate cancer. Our clinical experience suggests that soy supplementation using commercially available soy products can have durable beneficial effects on PSA levels and PSA kinetics in some men with prostate cancer.

AB - OBJECTIVE:: No standard therapeutic option exists for men with prostate cancer who have failed local therapy, have no gross metastatic disease, and whose only manifestation of disease is a rising prostate-specific antigen (PSA) level. Soy products are able to affect PSA kinetics in some men with prostate cancer, and this effect has been attributed to the decreased expression of the androgen receptor and other mechanisms. METHODS:: We treated 10 men with rising PSA levels after radical prostatectomy and salvage radiotherapy with commercially available soy products. Scans revealed no gross metastatic disease. Three men also had been receiving androgen-deprivation therapy (ADT) and had rising PSA levels that were consistent with castration-resistant (CR) disease. We reported the results of this modality on PSA levels, PSA kinetics, and the duration of PSA response. RESULTS:: Responses occurred in 4 of 7 (57%) patients with ADT-naïve disease and 1 of 3 (33%) patients with CR disease. The median duration of treatment response was 24 months. The overall clinical benefit, therefore, was noted in 5 of 10 (50%) patients. Therapy was well tolerated. CONCLUSIONS:: Our findings are fairly congruent with what has been described in the literature on the use of this modality in prostate cancer. We used commercially available soy products. We also show that soy can provide benefit in CR prostate cancer. Our clinical experience suggests that soy supplementation using commercially available soy products can have durable beneficial effects on PSA levels and PSA kinetics in some men with prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=80155201197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80155201197&partnerID=8YFLogxK

U2 - 10.1097/SMJ.0b013e3182335151

DO - 10.1097/SMJ.0b013e3182335151

M3 - Article

C2 - 22024780

AN - SCOPUS:80155201197

VL - 104

SP - 736

EP - 740

JO - Southern Medical Journal

JF - Southern Medical Journal

SN - 0038-4348

IS - 11

ER -